Inhibikase Therapeutics Inc [IKT] stock is trading at $1.96, down -2.00%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IKT shares have gain 13.95% over the last week, with a monthly amount glided 27.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inhibikase Therapeutics Inc [NASDAQ: IKT] stock has seen the most recent analyst activity on December 26, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $8. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on December 11, 2025, and set its price target to $4. On February 12, 2025, downgrade downgraded it’s rating to Neutral.
Inhibikase Therapeutics Inc [IKT] stock has fluctuated between $1.33 and $3.49 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Inhibikase Therapeutics Inc [NASDAQ: IKT] shares were valued at $1.96 at the most recent close of the market. An investor can expect a potential return of 104.08% based on the average IKT price forecast.
Analyzing the IKT fundamentals
Gross Profit Margin for this corporation currently stands at -0.9% with Operating Profit Margin at -1945.93%, Pretax Profit Margin comes in at -1813.85%, and Net Profit Margin reading is -1813.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.57 and Total Capital is -0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.85 points at the first support level, and at 1.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.11, and for the 2nd resistance point, it is at 2.26.
Ratios To Look Out For
For context, Inhibikase Therapeutics Inc’s Current Ratio is 11.67. Further, the Quick Ratio stands at 11.67, while the Cash Ratio is 5.72.
Transactions by insiders
Recent insider trading involved Sands Capital Life Sciences Pu, 10% Owner, that happened on Nov 21 ’25 when 2.07 million shares were purchased.
